Assessment of the Immunogenicity and Safety of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients With Rheumatic Diseases

Наумцева, М. С.; Белов, Б. С.; Александрова, Е. Н.; Тарасова, Г. М.; Новиков, А. А.; Каратеев, Д. Е.; Лучихина, Е. Л.; Волков, А. В.; Юдкина, Н. Н.; Антелава, Ольга Алексеевна; Khelkovskaia-Sergeeva, A.; Черкасова, М. В.; Муравьев, Ю. В.

doi:10.14412/1995-4484-2015-586-590

Cited by 3 publications

(1 citation statement)

References 20 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В.А. Насоновой, преобладание больных РА со средней и высокой степенью активности (84,7%) на исходном этапе, а также продемонстрированная значимая положительная динамика индекса DAS28 на протяжении годичного периода наблюдения позволяют вести речь о безопасности пневмококковой вакцинации, выполненной не только в неактивной стадии болезни, но и на фоне активного воспалительного процесса [7]. В то же время эксперты EULAR не исключают возможность вакцинации у больных с активной стадией болезни, но при этом решение должно приниматься с учетом особенностей каждого конкретного случая.…”

Section: рекомендации по вакцинации взрослых больных иврзunclassified

Vaccination in rheumatology (the 2019 update of EULAR recommendations)

Белов¹,

Тарасова²,

Муравьева³

2019

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

Section: рекомендации по вакцинации взрослых больных иврзunclassified

Vaccination in rheumatology (the 2019 update of EULAR recommendations)

Белов¹,

Тарасова²,

Муравьева³

2019

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

Vaccination in Rheumatology: New Data (Based on Recommendations of the European League Against Rheumatism)

Белов

Тарасова

Muravyova

2020

jour

Self Cite

View full text Add to dashboard Cite

Comorbid infections have a significant effect on morbidity and mortality in modern rheumatology, especially in immune-mediated inflammatory rheumatic diseases (IMIRD). In this regard, vaccination is becoming increasingly important in the prevention of infections in IMIRD. The article analyzes an updated version of the recommendations for vaccination of adult patients with IMIRD, proposed by experts of the European League Against Rheumatism at the end of 2019. The safety and immunogenicity of vaccination associated with the prevention of various infections in patients with IMIRD are discussed. The main directions of future research on this issue are outlined.

show abstract

Pneumococcal vaccination in rheumatic diseases: 10 years of application experience at the V.A. Nasonova Research Institute of Rheumatology

Белов¹,

Muravyeva²,

Тарасова³

et al. 2022

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

In the coming XXI century, infectious diseases still retain their importance both in medical and social terms, this problem is very relevant for rheumatology, where comorbid infections (CI) have a significant impact on both the course of the main immuno-inflammatory rheumatic disease (IIRD) and mortality. One of the leading places in the structure of serious CI in patients with IIRD is occupied by pneumonia, which is a weighty argument in favor of the vaccination of these patients from pneumococcal infection. The article presents generalized data on the use of 23-valent pneumococcal polysaccharide vaccine (PPV-23) in patients with IIRD who received inpatient and outpatient treatment at the V.A. Nasonova Research Institute of Rheumatology for the last 10 years. It has been shown that the vaccination of PPV-23 in patients with IIRD is characterized by high preventive efficacy (>90%), is safe and does not increase the risk of exacerbation of the disease. The sufficient immunogenicity of vaccination is evidenced by a significant increase in the levels of pneumococcal antibodies in the blood serum and the coefficient of post-vaccination response. The use of glucocorticoids (methylprednisolone, prednisolone) has no significant effect on the effectiveness, immunogenicity and safety of PPV-23 vaccination. The possibility of vaccination of PPV-23 with any activity of the process in patients with rheumatoid arthritis, systemic lupus erythematosus and spondyloarthritis (ankylosing spondylitis, psoriatic arthritis) with the condition of adequate therapy has been demonstrated. In order to develop clearer indications for vaccination, to determine time intervals for revaccination, to evaluate the effectiveness and safety of new pneumococcal vaccines, as well as to study the effect on the results of immunization of various anti-rheumatic drugs in patients with IIRD, further multicenter large-scale studies are needed.

show abstract

Assessment of the Immunogenicity and Safety of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients With Rheumatic Diseases

Cited by 3 publications

References 20 publications

Vaccination in rheumatology (the 2019 update of EULAR recommendations)

Vaccination in rheumatology (the 2019 update of EULAR recommendations)

Vaccination in Rheumatology: New Data (Based on Recommendations of the European League Against Rheumatism)

Pneumococcal vaccination in rheumatic diseases: 10 years of application experience at the V.A. Nasonova Research Institute of Rheumatology

Contact Info

Product

Resources

About